Acme India Industries Limited reversed Rs 53.6833 crore

Acme India Industries Limited reversed Rs 53.6833 crore of assets and liabilities associated with the proprietorship of promoter Suraj Pandey after a FY 2023-24 review found they did not belong to the acquired business. The adjustment comprised Rs 18.2472 crore of assets returned to Mr. Pandey and Rs 35.4361 crore of liabilities reversed for his discharge.

What did Acme India reverse from the business acquisition?

Acme India reversed Rs 18.2472 crore of assets and Rs 35.4361 crore of liabilities that had initially been transferred in connection with the acquisition of M/s Acme India, Mr. Pandey's sole proprietorship. The combined amount was Rs 53.6833 crore, although the disclosure describes the asset return and liability reversal as separate actions with different stated reasons.

The assets included Goods and Services Tax, or GST, credits, fixed deposit receipts, or FDRs, tax deducted at source, or TDS, receivables and other similar assets. Acme India said these balances had been transferred to the company during the acquisition, but its FY 2023-24 review determined that they were personal assets of Mr. Pandey and had not been intended to form part of the company's business assets.

The liability amount was Rs 17.1889 crore higher than the asset amount. Acme India stated that the Rs 35.4361 crore of liabilities was unrelated to the business acquired and did not form part of that acquisition, rather than saying that the liabilities had been settled by the company.

Why did Acme India reverse Rs 53.6833 crore of acquisition balances?

Acme India reversed the acquisition balances because its FY 2023-24 review concluded that the asset and liability items did not belong within the business acquired from the proprietorship. The company said the assets were personal to Mr. Pandey, while the liabilities were unrelated to the acquired business and were returned to the original proprietor for discharge at his own end.

The disclosure does not provide the original acquisition date, identify individual creditors behind the Rs 35.4361 crore liability balance or give a line-by-line value for the GST credits, FDRs and TDS receivables. It does, however, establish that the reason for both adjustments was the assessed boundary of the business acquisition, not an ordinary subsequent collection, payment or operating transaction.

The financial reporting consequence arises from the initial transfer of balances that were later found to sit outside the acquired business. Acme India expressly says the initial inclusion and subsequent return of the Rs 18.2472 crore asset balance may raise questions about the accuracy and consistency of its financial statements.

The disclosed amounts are material in comparison with certain reported current balances, though the source does not link those balances directly to the reversal. Restated standalone current assets were Rs 311.1718 crore at March 31, 2026, including trade receivables of Rs 263.0935 crore, while total current liabilities were Rs 185.7081 crore. These financial-statement figures are reported for a later date than the FY 2023-24 review.

What financial-reporting and creditor risks does Acme India disclose?

Acme India says the asset reversal could lead to regulatory scrutiny, audit qualifications or disputes concerning the treatment of the Rs 18.2472 crore of assets. The company does not disclose a regulatory finding, an audit qualification or a specific dispute that resulted from the FY 2023-24 review.

A regulatory review or audit qualification would concern whether the original acquisition accounting and later correction were appropriately reflected in the financial statements. The company says an unfavourable view by regulators or stakeholders could affect its financial position and credibility, but it does not quantify a potential penalty, adjustment or other financial outcome from that risk.

The Rs 35.4361 crore liability reversal creates a separate potential creditor issue. Acme India says creditors may dispute the non-transfer of their claims to the company, even though it states that those liabilities were not contractually undertaken by Acme India and were returned to the original proprietor for discharge.

The disclosure therefore presents company exposure as contingent on a creditor dispute or unforeseen claim, rather than as an established obligation. Acme India says litigation, settlements, costs and expenses associated with such claims could indirectly affect operations. It does not state that a creditor has filed a claim specifically tied to the liabilities returned to Mr. Pandey.

How does Acme India seek to limit exposure from the reversed liabilities?

Acme India says its directors have undertaken to indemnify the company against liabilities, claims, damages and expenses arising from the matter. An indemnity is an undertaking to compensate a party for specified losses, and the directors' commitment is the protection disclosed for potential claims connected with the reversed liabilities.

The indemnity does not remove the operational risk identified by Acme India. The company says that litigation, settlement costs and expenses may still indirectly affect its operations, which means the protection would need to apply and be available if a relevant claim or dispute emerges.

The disclosure also records historical compliance matters that are distinct from the Rs 53.6833 crore reversal but concern the company's governance framework. Acme India identified 34 delayed, erroneous or corrective filings with the Registrar of Companies between 2022 and 2025, involving forms such as annual returns, financial-statement filings, charges and allotments.

Acme India says it paid late fees or filed revised forms in several instances and has appointed a Compliance Officer to improve future compliance. It also says that a loan originally taken by the proprietorship and subsequently assumed by the company had been fully repaid, with no such liability outstanding as of the red herring prospectus date.

Conclusion

The FY 2023-24 review separated Rs 53.6833 crore from Acme India's acquisition treatment: Rs 18.2472 crore of assets was returned because it was identified as personal to Mr. Pandey, while Rs 35.4361 crore of liabilities was reversed because it was not related to the acquired business. The central reporting issue is the original inclusion and later removal of balances that the company says were outside the acquired business.

The next matter to watch is whether creditors challenge the non-transfer of claims linked to the Rs 35.4361 crore liability balance and whether the directors' indemnity is required. Acme India has disclosed a plan to strengthen compliance through a Compliance Officer and improved internal processes, while acknowledging that regulatory scrutiny, audit qualifications, disputes or related costs may still affect operations.